Multifaceted immune functions of human defensins and underlying mechanisms

Saahil Fruitwala\textsuperscript{b}, Darine W. El-Naccache\textsuperscript{a,b}, and Theresa L. Chang\textsuperscript{a,b,*}

\textsuperscript{a}Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers, the State University of New Jersey, New Jersey Medical School, Newark, NJ, USA

\textsuperscript{b}Public Health Research Institute, Rutgers, the State University of New Jersey, New Jersey Medical School, Newark, NJ, USA

Abstract

Defensins have been long recognized as natural antimicrobial peptides, but they also possess diverse and versatile immune functions. Defensins can both induce inflammation and suppress inflammatory responses by acting on specific cells through distinct mechanisms. Defensins can also modulate the immune response by forming a complex with cellular molecules including proteins, nucleic acids, and carbohydrates. The mechanisms of defensin-mediated immune modulation appear to be cell-type and context specific. Because the levels of human defensins are often altered in response to infection or disease states, suggesting their clinical relevance, this review summarizes the complex immune functions of human defensins and their underlying mechanisms of action, which have implications for the development of new therapeutics.

Keywords

Defensins; Immune functions; Pathways

1. Introduction

Defensins are antimicrobial peptides known to protect the host through their direct or indirect activities on microbes \cite{1,2,3}, although recent studies have demonstrated their ability to promote viral infectivity \cite{4,5}, indicating a complex role of defensins in host defense in a microbe, defensin, cell-type specific manner. As major players at the front line of defense, there has been much discussion of the immunological activities of defensins and their role as alarmins in host defense \cite{1,6,7,8}. Here, we focus on the immune functions of human defensins that are beneficial or detrimental to the host. We highlight advances in our understanding of the molecular mechanisms of immune modulatory activities of human defensins.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

\textsuperscript{*}Corresponding author at: Public Health Research Institute, Rutgers, New Jersey Medical School, 225 Warren Street, Newark, NJ 07103, USA. Theresa.chang@rutgers.edu (T.L. Chang).

Conflict of interests
The authors have declared that no conflict of interest exists.
2. Overview of human defensins and their regulation

Human defensins are cationic peptides of approximately 30 amino acids; they are classified into two subfamilies, α- and β-defensins, based on their disulfide bond linkages (Fig. 1, reviewed in [1,3,9]). Most human defensins within the same family have similar structure, and form dimers or oligomers [3,10,11]. However, dimers of human α-defensins, e.g., HNP3 (human neutrophil peptide 3) and human β-defensins, e.g., hBD2 (human β-defensin 2), are topologically distinct [12]. Human defensins are synthesized as a pre-pro-peptide, and are then processed intracellularly or extracellularly depending on the defensin and cell type (reviewed in [1]). In humans, there are 6 α-defensins: HNPs1–4 and human α-defensins 5 and 6 (HD5 and HD6). Six human β-defensins (hBD1–6) have been characterized [7,11,13], although gene-based analysis suggests that there are an additional 28 hBDs [14].

Human defensins are produced mainly by leukocytes and epithelial cells. HNPs1–3, which differ by single amino acid substitutions, are predominantly produced by neutrophils [15]. HNP4, comprising less than 2% of defensins in neutrophils, has a relatively distinct sequence but similar structure as HNPs1–3 [10,16]. While neutrophils produce the largest amounts of HNPs, these peptides are also found in other immune cells (reviewed in [17]). Cells can absorb and internalize HNPs [18–20], underlying the complexity of defining true HNP-producing cells. HNPs have been detected in placenta, spleen, thymus, intestinal mucosa, saliva, and cervical mucus plugs, and are released by neutrophils in response to chemokines, FCγ receptor cross-linking, phorbol myristate acetate (PMA), and bacterial products that trigger Toll-like receptors (TLRs, reviewed in [1,17]).

Although leukocyte α-defensins are conserved evolutionally and have been isolated from many species, mice do not express neutrophil α-defensins [1]. Mice do, however, express numerous cryptdins, which are enteric α-defensins, in intestinal Paneth cells [1,21]. Similarly, HD5 and HD6 are produced predominantly by intestinal Paneth cells in humans [22]. HD5-transgenic mice are markedly resistant to oral challenge with virulent Salmonella typhimurium, indicating that human and mouse enteric defensins have distinct functions [23]. HD5 can be found in other tissues such as the salivary glands, female genital tract, kidney, urinary tract, and inflamed colon (reviewed in [17,24]); intestinal HD6 expression is elevated in the presence of colon cancer [25,26]. NOD2 and Wnt signaling transcription factor TCF-4 proteins play a role in modulating HD5, but TCF4-mediated HD5 regulation does not depend on NOD2 [27,28]. HD5 is induced at the genital mucosa in patients with bacterial vaginosis, Neisseria gonorrhoeae (GC), and Chlamydia trachomatis infections [29,30]. Induction of HD5 and HD6 gene expression in GC-exposed cervicovaginal epithelial cells contributes to GC-mediated enhanced HIV infectivity [31]. HD6 gene expression is upregulated by atonal homolog 1 and β-catenin in colon cancer cell lines, DLD1 and SW480 [32]. The TCF4 binding site and E-box site in the proximal promoter region are critical for HD6 gene expression. Expression of HD6 but not HD5 is downregulated in non-inflamed jejunum of patients with Crohn’s disease [32]. In aggregate, the evidence indicates that levels of defensins are often altered in response to infection, inflammation, or tissue damage (reviewed in [1,17,33]), indicating an immune regulatory role in disease pathogenesis.
hBDs1–3 are mainly expressed by epithelial cells, but are also found in hematopoietic cells including peripheral blood mononuclear cells (PBMCs), monocytes, macrophages, plasmacytoid dendritic cells (pDCs), and monocyte-derived dendritic cells (MDDCs) (reviewed in [1,7,17]). Expression of hBDs4–6 is limited to specific tissues [13]. hBDs1–3 can be induced by cytokines, TLR activation, or viral exposure, but the underlying mechanisms of gene regulation of each hBD appear to be distinct [1,11,17,34]. Although hBD1 is often constitutively expressed, induction of hBD1 gene and protein expression has been observed in pDCs and monocytes in vitro and in lungs of mice in response to viral exposure [35]. hBD2 is induced by TLR2, TLR3, TLR4, TLR7, NOD1, and NOD2 signaling, important for sensing pathogens, in various epithelial cells and keratinocytes (reviewed in [17]). For example, TLR3 activation induces hBD1 and hBD2 expression in uterine epithelial cells and keratinocytes [35,36], and increases hBD2 and hBD3 expression in bronchial epithelial cells [37]. In oral epithelium, TLR2 and NOD1/2 ligands synergistically induce hBD2 expression through nuclear factor-κB (NF-κB) [38]. TLR2 or TLR4 activation induces hBD2 expression in keratinocytes and vaginal epithelial cells [39,40]. Cytokines including IL-17, IL-22, oncostatin M, TNFα, or IL-1α can induce hBD2 and hBD3 [41–44]. IL-17, important for maintaining mucosal homeostasis, upregulates hBD2 in primary human airway epithelium through JAK and NF-κB pathways [42]. However, NF-κB-dependent induction of hBD2 by IL-17A is mediated by the PI3K pathway and MAPK pathway in airway epithelial cells, whereas regulation of hBD2 by NF-κB is not dependent on the PI3K pathway in bronchial epithelial cells, [45–47], indicating that specific pathways involved in regulation of hBD2 are cell-type dependent. IL-22 can act together with IL-17 to induce hBD2 in keratinocytes in a synergistic or additive fashion [43]. TNF-α induces hBD2 but not hBD3 gene expression in a dose-dependent manner in human keratinocytes [48]. Unlike hBD-2, hBD-3 mRNA is preferentially stimulated by IFNγ rather than TNFα, indicating specific hBD regulation in response to specific cytokines. PMA, EGF, IFNγ, and IL-1β induce hBD3 gene expression in human oral epithelial cells and in TR146 oral cancer cells [44]. EGF-mediated hBD3 induction is blocked by inhibitors of MEK1/MEK2, p38 MAPK, PI3K, and PKC but not by JAK and STAT3 inhibitors [44]. Taken together, there are common pathways involved in induction of both hBD2 and hBD3 but some pathways are dependent on cell types and stimuli.

3. Human α-defensins

3.1. Inflammatory activities of human α-defensins

Neutrophils are often the first cells that are recruited to the site of an infection, where they release effector molecules such as HNPs [49]. Although HNPs exhibit direct and potent antimicrobial activities [3], these peptides also control infection through modulating various immune activities including chemotaxis, phagocytosis, and cytokine induction during acute infection. However, uncontrolled inflammation can lead to tissue damage and worsen disease progression. HNPs1–3 act as chemoattractants for various types of immune cells including monocytes, immature DCs, and naïve CD4+ T cells but not for memory CD4+ T cells or mature DCs [7,50–52]. HNPN1 and HNPN3 also induce the migration of macrophages and mast cells but not DCs [53]. HNPN1 and HNPN2 aggregate influenza virus A and bacteria including Staphylococcus aureus (Gram positive) and E. coli (Gram negative) and increase...
phagocytosis [54]. HNP1 induces TNFα in PBMCs [55]. HNPs also upregulate the expression of CC-chemokines and IL-8 in macrophages and epithelial cells, respectively [56,57]. HD5 but not the linear HD5Abu mutant, in which cysteine residues are replaced with L-α-aminobutyric acid, induces IL-8 in the intestinal epithelial Caco-2 cell line [58]. HD5 and TNFα have a synergistic effect on IL-8 production [58], indicating the role of defensins in modulating activities of cytokines.

Antimicrobial peptides can act on immune cells directly or can modulate immune responses by forming a complex with other molecules. The most well characterized example is the antimicrobial peptide LL37, which forms a complex with self-DNA to activate pDCs and monocytes through TLR9 [59,60]. LL37 also complexes with self-RNA to activate pDCs (through TLR7) and myeloid DCs (mDCs) through TLR8 [61]. In response to infection and inflammation, activated neutrophils release neutrophil extracellular traps (NETs), composed of HNPs and self-DNA [62]. NETs found in patients with systemic lupus erythematosus activate pDCs through TLR9 [63]. Although the complex of HNPs and DNA is not sufficient to induce IFNα production by pDCs, HNPs can promote pDC activation by suboptimal concentrations of LL37 through protecting DNA degradation [63]. HNPs can bind to other host proteins to modulate immune or metabolic functions [8]. HNPs bind to low-density lipoprotein receptor-related proteins and interact with protein kinase Ca and β, leading to decreased smooth muscle contraction in response to phenylephrine [64]. HNPs also interact with adrenocorticotrophic hormone receptors and heparan sulfate proteoglycan to modulate other biological activities [65,66]. HNP1 inhibits the activity of conventional PKC isoforms in a cell-free system [67]. This PKC inhibitory activity appears to be involved in HNP1-mediated inhibition of HIV replication in primary CD4+ T cells [68], and is involved in suppression of influenza A virus in lung epithelial cells [69]. Although the role of PKC in defensin-mediated immune modulation has not been characterized extensively, the PKC inhibitor blocks the ability HNP1 and HD5 to desensitize hBD2 in human primary macrophages [53]. Additionally, HNP1 blocks the classical and lectin pathways of complement activation by binding to complement C1q and to mannose-binding lectin, respectively [70,71].

3.2. Anti-inflammatory activities of human α-defensins

Regulation of initial inflammation in response to infection is crucial for maintaining immune homeostasis. Although defensins are known to induce immune responses, their anti-inflammatory activity has also been documented. HNP1 and HNP4 suppress NK cell activity and production of IFNγ and IL-6 by PBMCs in response to phytohemagglutinin (PHA) or concanavalin A stimulation [72]. HNPs in conditioned media from TNFa-stimulated polymorphonuclear leukocytes (PMNs) may contribute to suppressed PMN migration [73]. Indeed, HNP1 suppressed PMN migration in response to formyl-methionyl-leucyl-phenylalanine, a potent chemotactic peptide for PMNs [73]. Lectin-like soluble factors such as HNPs from apoptotic and necrotic neutrophils inhibit LPS-mediated TNFα induction by monocyte-derived macrophages (MDMs) [74]. HNP1 potently induces TNFα production in MDMs, promotes phagocytic activity, and plays a major role in this anti-inflammatory effect in LPS-stimulated MDMs and in a murine peritonitis model [74]. Linear HNP1 does not have an anti-inflammatory effect. HNP1 dampens live or dead Pseudomonas aeruginosa-
mediated cytokine production (TNFα, IL-1β, and IL-8) but does not reduce the bacterial burden [74]. HNP-1 also blocks IL-6 production by TLR7/8 or CD40L/IFNγ, mimicking T cell engagement [75]. Tertiary structure is required for the cytokine inhibitory effect as linearized HNP and the W26A mutation, which disrupts dimerization, abrogate the ability to block cytokine induction. Mechanistically, HNP1 is internalized and binds to mRNA in a sequence-independent manner to block translation [75].

Paneth cell defensin-deficient mice (MMP-7−/−) have a higher baseline level of intestinal IL-1β, and are more susceptible to dextran sulfate sodium-induced colitis [55]. HD5 reduces the Th1 inflammatory phenotype in NOD2−/− mice in response to bacterial infection [76]. Both HNP1 and HD5 block ATP-induced IL-1β release from LPS-activated monocytes. The blockade of IL-1β release is not mediated through inhibition of caspase 1 activity. Treatment with HNP-1 or HD5 leads to a reduction of newly synthesized cell-associated pro-IL-1β proteins in LPS-activated monocytes in response to ATP, suggesting that human α-defensins may destabilize pro-IL-1β [55].

3.3. Receptors and signaling involved in immune functions of human α-defensins

The chemotactic effect of HNPs on both T cells and dendritic cells is sensitive to pertussis toxin (PTX), suggesting the involvement of Gaα protein-coupled receptor [52]. Similarly, the induction of migration of macrophages and mast cells by HNP1, HNP3, and HD5 are sensitive to PTX and MAPK inhibitors PD098059 and SB203580, indicating that Gaα protein-coupled receptor and MAPK ERK1/2 and p38 play roles in the chemotactic activity of human α-defensins [53]. The specific receptors for the chemotactic effects of HNPs in specific immune cells remain to be identified. With respect to receptors for HNP-mediated cytokine induction, HNPs induce IL-8 through G-protein coupled nucleotide receptor P2Y6 in lung epithelial cells [77], and HNP-1 suppresses neutrophil apoptosis through the P2Y receptor pathway [78]. The purinergic P2 receptor but not the P2Y6 receptor is involved in HNP1-mediated IL-8 induction [79]. Activation of ERK1/2 and PI3K/Akt but not Src is required for HNP-mediated IL-8 induction; however, Src is required for IL-8 release in monocytic cell lines in response to HNPs [80]. Although HNP1 activates ERK1/2 and p38, ERK1/2 is involved in HNP1-mediated IL-8 induction through P2 receptors, but this is independent of P2Y6 receptors [52,79]. In pDCs, HNP-1 induces production of IFNα, IFNβ, and IL-6, and enhances TLR9 activation through Nf-κB and IRF1 pathways [81], although the interplay between these two pathways in activation of pDCs remains to be determined. In the LPS-primed THP1 monocytic cell line, HNP-1 activates NLRP3 inflammasome and induces the release of IL-1β [82]. HNP-1 binds to the ATP-gated ion channel receptor, P2X7, and triggers P2X7- potassium (K⁺) efflux-caspase-1 signaling pathway, leading to pyroptotic pore formation and enhancement of the inflammatory response [82]. Receptors and pathways involved in the immune functions of HNPs are summarized in Table 1.

4. Human β-defensins

The immune functions of hBDs, particularly hBD2 and hBD3, have been studied extensively. hBDs chemoattract immune cells, induce cytokines/chemokines, and modulate cellular functions and differentiation/activation markers. Although findings pertaining to the
precise roles of receptors and cell signaling in the functions of hBDs have not been wholly consistent. Ga\textsubscript{i} protein-coupled receptors and MAPK signaling appear to play a key role in multiple immune functions of hBDs (Table 1).

### 4.1. hBD1

Similar to HNP-1, hBD1 chemoattracts MDDCs, upregulates costimulatory markers CD80, CD86, and CD40, upregulates maturation markers CD83 and HLA-DR, upregulates scavenger receptor CD91, induces production of TN\textsubscript{α}, IL-6, and IL-12p70, and enhances DC-mediated T cell proliferation [83]. hBD1 also induces the migration of immature mast cell line HMC-1 in a dose-dependent manner [84]. hBD1 induces migration of HEK293 expressing CCR6, the receptor for chemokine ligand 20 (CCL20; also known as MIP-3\textalpha) [85]; however, the role of CCR6 in immune functions of hBD1 in primary cells is not well established.

hBD1 mRNAs are upregulated in pDCs and monocytes in response to infection by influenza, HSV-1, and Sendai virus [35]. However, hBD1 gene expression is suppressed in normal human bronchial epithelial cells in response to influenza virus infection and in human gingival epithelial cells in response to HSV-1 infection [35], indicating cell-type specific hBD1 gene regulation. In response to influenza virus challenge, murine β defensin 1, mBD1(−/−) mice have more severe pathological scores than C57BL/6 wild-type mice despite the fact that the virus titers in the lung are comparable and that there is an increase in inflammatory influx in the lung of infected-mBD(−/−) mice [35]. The elucidation of the details of the mechanism by which hBD1 or mBD1 in epithelial cells and pDCs controls viral infection will require further investigation.

### 4.2. hBD2/hBD3

hBD2 up-regulates IL-1β, IL-6, IL-8, IL-10, MCP-1, MIP-1β, and RANTES in PBMCs [86], and exhibits multiple activities on mast cells, including induction of cell migration, degranulation, and production of prostaglandin D\textsubscript{2} [87]. Studies on the role of hBDs in skin inflammation demonstrate the interplay between hBDs and inflammatory cytokines (reviewed in [6]). Elevated levels of IL-17A, IL-22, oncostatin M, TN\textsubscript{α}, and IL-1\textalpha are found in psoriatic skin, and these cytokines can induce hBD2 and hBD3 in skin explants [41]. In atopic dermatitis, hBD2 enhances IL-22 and oncostatin M production [81], hBD3 enhances IL-4, IL-13, and IL-31 production in CD3/28-stimulated T cells, suggesting it plays a role in Th2 responses [88]. Conversely, IL-22 and oncostatin M promote induction of hBD2 and hBD3 in keratinocytes. STAT3 and p38 MAP kinase pathways are involved in IL-22-induced hBD2/3 production. MEK is involved in oncostatin M-induced hBD2/3 induction, whereas the NF-κB pathway is involved in oncostatin M-mediated production of hBD2 but not of hBD3 [88]. The interplay between hBDs and cytokines in immune regulation as well as the control of their immune activation require further investigations.

#### 4.2.1. Receptors involved in immune functions of hBD2/hBD3

**4.2.1.1. CCR6:** hBD2 induces the migration of immature DCs and memory CD4+ T cells through CCR6 [85], hBD2 binds to HEK293T cells expressing CCR6 but not CXCR4, CCR1, or CCR5. The chemotactic activity of hBD2 can be blocked by MIP-3\textalpha, anti-CCR6. 

Semin Cell Dev Biol. Author manuscript; available in PMC 2019 April 26.
antibody, or pertussis toxin [85]. hBDs1–4 induce migration of MDMs, although hBD3 has a less potent effect [84]. In contrast to the finding by Yang et al. [85], Soruri and colleagues have shown that hBD2 and hBD3 have no chemotactic effect on memory cells, and have a weak effect on DCs. Additionally, hBD2 and hBD3 do not induce the migration of the CCR6 stably transfected cell line RBL-2H3 [84]. However, hBD2-mediated chemotaxis of MDMs is sensitive to PTX, and can be blocked by inhibitors of ERK, JNK, and p38 MAPK [84]. The lack of involvement of CCR6 in hBD2-mediated chemotaxis of MDMs may due to low levels of cell surface receptors. For example, hBD2 but not hBD1 induces the migration of neutrophils in response to TNFa, which induces CCR6 expression [89]. The chemotactic effect of hBD2 on TNFa-stimulated neutrophils is dependent on CCR6, and is sensitive to PTX and a phospholipase C (PLC) inhibitor, indicating the involvement of the Gαi protein-coupled PLC pathway in the action of hBD2 on activated neutrophils [89]. The Gαi protein-coupled PLC pathway is also involved in the chemotactic effect of hBD2 on mast cells [90].

CCR6 is also involved in hBD-mediated cytokine production and in apoptosis. Plasma levels of hBD1 and hBD3 but not hBD2 are elevated in asthmatic patients [91]. hBD3 induces IL-8 in human airway smooth muscle cells in a CCR6-dependent manner. hBD3 also induces apoptosis via an ERK1/2 MAPK dependent pathway. Mitochondrial ROS induction is involved in hBD3-mediated IL-8 induction and apoptosis [91]. hBD3 but not hBD1, 2, or 4 prevent spontaneous neutrophil apoptosis in a dose-dependent manner [92]. hBD-3, but not hBD1, hBD2, or hBD4 significantly suppresses activation of caspase 3. hBD3 down-regulates truncated Bid, but up-regulates Bcl-xL [92]. hBD3 suppresses membrane potential change in mitochondria. The suppression of neutrophil apoptosis by hBD3 is mediated through CCR6 [92]. hBDs play a role in intestinal homeostasis, and hBD2 is often down-regulated in inflamed intestines [93]. While hBD2 does not have an effect on the growth or death of the intestinal epithelial cell line HT29, it promotes wound healing of intestinal epithelial cells in vitro by induction of mucins Muc 2 and 3 [94]. hBD2 also induces cell migration via a CCR6 dependent mechanism, and blocks TRAIL-mediated apoptosis, suggesting that hBD2 contributes to the maintenance of epithelial barriers [94].

A role of CCR6 in the interplay between hBDs and mucosal immune mediators has been demonstrated [95]. TCR activation with anti-CD3/CD28 antibodies significantly induces CCL20, IL-17, and IL-22 in Th17 cells, and IL-17 further induces hBD2 but not hBD1 or hBD3 [95]. CCL20 and hBD2 increase the numbers of Th17 cells but not the numbers of Th1 or Th2 cells that adhere to inflamed endothelial cells in response to IL-1β and TNFa, both of which upregulate CD54 (ICAM-1). Although CCL20 often has a more potent chemotactic activity than hBD2, both CCL20 and hBD2 have comparable effects on the adherence of Th17 cells to inflamed endothelial cells or fibroblasts [95]. Adherence to Th17 cells is dependent on CCR6 but not CXCR4. Prolonged TCR activation down-regulates CCR6, which may restrict the migration of cells to inflamed sites.

**4.2.1.2. CXCR4, CCR2.** In addition to CCR6, other chemokine receptors have been shown to play a role in the immune functions of hBD2/hBD3. hBD2 or hBD3 but not hBD1 down-regulates surface expression of CXCR4 on PBMCs [96]. hBD3 blocks CXCR4-dependent chemotaxis in a CD4+ T Jurket cell line and in primary activated CD4+ T cells induced by CXCL12/SDF1α. hBD3 induces internationalization of CXCR4 by the
transformed CD4+ CEM T cell line [96,97]. The interaction between hBD3 and CXCR4 was further demonstrated by the ability of hBD3 to compete with SDF-1α [97]. Pre-incubation of hBD3 also blocks calcium mobilization induced by SDF-1α but not by RANTES in differentiated THP-1 cells; SDF-1α induces ERK1/2 phosphorylation in CEM and primary CD4+ T cells [97]. Interestingly, expression of hBD2 and 3 and their mouse orthologs mBD4 and mBD14 as C-terminal fusion proteins human IgG1 Fc shows that defensin-IgFc fusion proteins bind to and induce migration of HEK293 cells expressing CCR2 but not CXCR4 [98]. The chemotactic activity of hBD2 and mBD4 Ig fusion proteins is apparent at concentrations as low as 1 ng/ml, and reaches the maximal effect at 100 ng/ml, whereas hBD3 and mBD14 IgFc fusion proteins require 10–100 ng/ml for chemotaxis of HEK293 cells expressing CCR2. Interestingly, hBD3 and mBD14 IgFc fusion proteins but not hBD2 or mBD4 IgFc fusion proteins at 1 ng/ml have chemotactic activity for peripheral monocytes. All defensins chemoattract murine peritoneal exudate cells that express CCR2 but not CCR6 [98]. It’s apparent that the chemotactic activities of defensins are cell-type dependent. It remains to be determined whether the defensin-Ig fusion protein represents native defensins. For example, hBD2 is known to form higher order oligomers [12], although it’s not clear whether the higher order structure is required for the binding to the receptor. hBD3 induces the expression of IL-1α, IL-6, IL-8, CCL18, and TNFα by MDMs, and recruits monocytes/macrophages through CCR2 [99]. Disruption of intrachain disulfide bonds in hBD3 abolishes its chemotactic but not its antimicrobial activities [100].

4.2.1.3. TLRs: mBD2 can recruit bone-marrow-derived immature DCs through CCR6, and can induce DC maturation through TLR4 [101]. In humans, hBD3 induces expression of costimulatory markers on antigen presenting cells [102]. Stimulation of PBMCs with recombinant or synthetic hBD3 leads to increased levels of surface expression of CD80, CD86, and CD40 on myeloid dendritic cells and monocytes but not on pDCs or B cells [102]. Activation of monocytes by hBD3 is mediated through MyD88 and IRAK-1 activation. The JAK2 inhibitor (AG490) has no effect on blocking activation of monocytes by hBD3. Activation of NF-κB by hBD3 in transformed cell lines is mediated through TLR2 coupling with TLR1 but not with TLR6 [102]. Pre-incubation of PBMCs with anti-TLR1 and TLR2 antibodies suppresses induction of CD80 by hBD3, confirming a role of TLR1 and TLR2 in hBD3-mediated activation of antigen presenting cells [102]. Although both hBD3 and Pam3CSK4 (TLR1/2 agonist) induce IL-1β through TLR1/2 receptor signaling in monocytes, Pam3CSK4 but not hBD3 induces IL-10, resulting in down-regulation of CD86 on monocytes [103]. Of the MAP kinases, neither JNK1/2 nor p38 appears to be involved in the differential ability of hBD3 and Pam3CSK4 to induce IL-10, as both stimuli activate MAP kinases. However, Pam3CSK4 but not hBD3 activates non-canonical NF-κB pathway. IL-10 down-regulates hBD3-mediated CD86 induction in monocytes [103]. Pam3CSK4 and hBD3 synergistically induce IL-1β production in monocytes. However, hBD3 has no effect on IL-10 induction by Pam3CSK4, indicating that hBD3 does not complete for the binding of Pam3CSK4 to TLR1/2 receptors [103]. hBD3 induces expression of stimulatory receptor CD69 on NK cells through TLR1/TLR2, and this induction is facilitated by CCR2 [104]. hBD3 induces NK cell-mediated IFNγ secretion and promotes mDC-dependent NK cell cytotoxic activity [104].
4.2.1.4. P2X7R: hBD3 at high concentrations (greater than 5 μM) causes membrane damage, mediated by negatively charged phospholipids, in monocytes but not in B cells or T cells [105]. hBD3 induces membrane repair mechanisms as indicated by an increase in surface LAMP, a membrane repair marker. hBD3 activates monocytes by upregulating CD80 and CD86 [106]. Induction of expression of CD86 by hBD3 is mediated through P2X7R; however, hBD3 induces CD80 expression through P2X7R-independent pathways, and does not directly activate P2X7R ion channel function [106]. It was suggested that hBD3 activates P2X7R through autocrine ATP release from both live and lytic cells [106].

4.2.1.5. MrgX2: Human mast cells express G protein-coupled receptor, Mas-related gene X2 (MrgX2), which is involved in hBD-mediated mast cell degranulation [107]. hBD2 and hBD3 induce Ca\(^{2+}\) mobilization and degranulation in mast cells [107]. In contrast to the chemotactic effect of hBDs on dendritic cells, T cells, and monocytes via CCR2, CCR6, and TLRs [85,98,102], the activity of hBD2 and hBD3 in mast cells is not sensitive to PTX. CCL2 does not induce Ca\(^{2+}\) mobilization, suggesting that neither CCR6 nor CCR2 is involved. Interestingly, PTX, La\(^{3+}\), or 2-aminoethoxydiphenyl borate (2-APB, a dual inhibitor of inositol 1, 4, 5, triphosphate receptor and transient receptor potential channels) blocks hBD-mediated degranulation in mast cells.

4.2.1.6. STAT signaling: In activated CD4+ T cells, hBD3 does not induce ERK1/2 or p38 MAP kinases [108]. hBD3 but not hBD2 activates STAT1 phosphorylation, although the significance of hBD3-mediated STAT1 phosphorylation in T cell functions is not well defined [108]. The role of STAT signaling pathways in the crosstalk between defensins and cytokines remains to be determined. In keratinocytes, TNFα/IFNγ stimulation induces hBD2 and hBD3 by activating STAT1 and NF-κB signaling [109]. Activation of STAT6 and suppressors of cytokine signaling-1 and -3 inhibit TNFα/IFNγ mediated-induction of hBD2 and hBD3 by interfering with STAT1 and NF-κB signaling [109]. Further studies on the autocrine or paracrine effect of hBD involved in STAT pathways would offer a better understanding of the role of STAT signaling in regulation of hBDs and their functions.

4.2.2. Role of hBD2/hBD3 in modulation of TLR responses—hBD2 and hBD3 do not induce either TNFα or IL-6 production in macrophages; however, hBD3 can suppress LPS-mediated TNFα and IL-6 production in the monocyctic THP-1 cell line. MDMs, murine transformed cell line RAW264.7, and murine BMDMs [110], hBD3 also suppresses TNFα induction in BMDMs in response to IFNγ and CD40L, but does not have an effect on TLR1/2-mediated TNFα induction. Additionally, hBD3 reduces TNFα production in mice. Anti-inflammatory activity is not mediated through melanocortin receptors, nor through IL-10 or cAMP [110]. Inhibition of the TLR4 signaling pathway by hBD3 is dependent on MyD88 or TRIF pathways, indicating an anti-inflammatory role for hBD3 [111]. hBDs induce TLR3-mediated induction of TNFα, IFNβ, IL-6, and IL-8 in BMDMs [112]. hBD3 promotes TLR3-mediated IFNβ production through the MDA5/MAVS pathway, but suppresses CXCL10 through TRIF signaling [112]. It is worth noting that pre-treatment of hBD2-IgFc or hBD3-IgFc fusion proteins enhance, rather than suppresses, TLR responses in macrophages through induction of extracellular ATP, which is followed by action of P2X7R [113].
Both hBD2 and hBD3 promote IFNα production by pDCs by binding to self DNA or CpG oligonucleotides to form DNA complexes. hBD3 promotes TLR9-mediated activation of pDC and mDC in vitro and in mice, suggesting an adjuvant activity of hBD3 as well as involvement in skin inflammation [114]. In this regard, hBD2 and hBD3 are found in psoriatic skin lesions, and promote pDC activation [115]. Synthetic hBD3 but not hBD1 enhances TLR9-dependent IFNα induction by pDC in response to self-DNA. Although higher concentrations of hBD2 are required to activate pDCs in the presence of genomic DNAs, both hBD2 and hBD3 have comparable synergistic effects on LL37-mediated pDC activation. Similar to LL37-mediated pDC activation in response to TLR9 [59,63], hBD2 and hBD3 aggregate DNA and protect host DNA from DNAse I degradation, allowing internalization into endosomal compartments for TLR9 activation [115]. hBD3 also promotes TLR9-mediated IFNα and IL-6 induction in murine Flt-3-induced DCs and PBMCs in response to bacterial DNAs [116]. The effect is more pronounced in cDCs (CD11c + B220-) than in pDCs (CD11c + B220high). hBD3 aggregated DNA and increased the uptake of DNA into murine DCs [116].

4.3. hBD6

Structural analysis indicates that hBD6 binds to a peptide derived from the extracellular domain of CCR2 [117]. hBD6 forms a complex with glycosaminoglycans (GAG) in a 2:1 stoichiometry [118]. The GAG binding site overlaps with CCR2 binding sites as indicated by the replacement of CCR2 sulfopeptides by increased amounts of GAG [118]. The role of CCR2 or GAG in the immune functions of hBD6 as well as putative competition between CCR2 and GAG in the hBD6 activity remain to be established.

4.4. The immune modulatory role of hBDs in carcinogenesis

Elevated CCR6 and CCR7 expression has been found in metastatic squamous cell carcinoma of the head and neck (SCCHN) [119], suggesting immune modulation of cancer cell migration. hBD3 induces CCR7 expression on primary SCCHN tumor cells and promotes tumor cell migration toward CCL19 in a NF-κB dependent manner [120]. hBD3 is internalized into tumor cells via endocytosis. The induction of CCR7 by hBD3 is not mediated through a G-protein coupled receptor pathway or by TLR signaling, shown by the fact that the induction is not inhibited by PTX or inhibitors of TLR signaling (MyD88 or TRIF-peptide inhibitor). hBD3 protects cisplatin-mediated apoptosis of SCCHN cells through the PI3/Akt pathway, indicating a role of hBD3 in promoting cancer cell survival [120].

hBDs play a role in oral tumorigenesis (reviewed in [121]). In normal oral epithelium, hBD1 and hBD2 are expressed in differentiated cells near the keratinized superficial layer, whereas hBD3 is expressed in the proliferative cells in the basal layers of oral epithelium [44,122]. In oral biopsy samples of moderate dysplasia, hBD3 expression is also found in dysplastic cells near the spinosum layer [44]. hBD1 and hBD2 are not found in the carcinoma in situ (CIS), whereas hBD3 is highly expressed in pre-malignant cells in CIS. The overexpression of hBD3 is associated with infiltration of macrophages into the site of the lesion, suggesting a role of hBD3 in progression of oral cancer [44]. In the nude mouse model, hBD3 is
associated with macrophage recruitment to the lesions, and the induction of infiltration of tumor-associated macrophages by hBD3 is mediated through CCR2 [99].

5. Conclusions

Defensins have multifaceted immune functions that can be critical both for combating pathogens and for disease progression. Understanding the immune functions of defensins will continue to be an exciting and important area of research. To advance the field, caution should be taken to avoid contamination. Rigorous controls are needed when analyzing the activities of defensins in myeloid cells, which are highly sensitive to TLR agonists. Further delineation of the role of critical determinants and of the higher order structure of defensins with respect to their immune functions may help in the design of multi-purpose defensin analogs to combat pathogens through direct antimicrobial activities and indirect immune modulatory activities. Because the activity of defensins is cell-type specific, studies using complex models (e.g., explants in an air-liquid culture) will likely offer insight into mucosal immune functions of defensins. A more thorough comparative analysis of the properties of human defensins and their murine orthologs as well as appropriate animal models to validate the role of receptors and signaling pathways in defensin-mediated immune functions will help address the immune functions of defensins in complex models. Additionally, identification of attributes that direct inflammatory and anti-inflammatory functions of defensins will be crucial for their development as new immunotherapeutics.

Acknowledgement

This work was supported by NIHAI081559 (to T.L.C).

References

[1]. Ganz T, Defensins: antimicrobial peptides of innate immunity, Nat. Rev. Immunol 3 (9) (2003) 710–720. [PubMed: 12949495]
[2]. Klotman ME, Chang TL, Defensins in innate antiviral immunity, Nat. Rev. Immunol 6 (6) (2006) 447–456. [PubMed: 16724099]
[3]. Lehrer RI, Lu W, Alpha-defensins in human innate immunity, Immunol. Rev 245 (1) (2012) 84–112. [PubMed: 22168415]
[4]. Rapista A, Ding J, Benito B, Lo YT, Neiditch MB, Lu W, Chang TL, Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment, Retrovirology 8 (1)(2011)45. [PubMed: 21672195]
[5]. Wilson SS, Bromme BA, Holly MK, Wiens ME, Gounder AP, Sul Y, Smith JG, Alpha-defensin-dependent enhancement of enteric viral infection, PLoS Pathog. 13 (6) (2017) e1006446. [PubMed: 28622386]
[6]. Niyonsaba F, Nagaoka I, Ogawa H, Human defensins and cathelicidins in the skin: beyond direct antimicrobial properties, Crit. Rev. Immunol 26 (6) (2006) 545–576. [PubMed: 17341194]
[7]. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ, Multipleroles of antimicrobial defensins, cathelicidins, and eosinophil-derivedneurotoxin in host defense, Annu. Rev. Immunol 22 (2004) 181–215. [PubMed: 15032578]
[8]. Rehaume LM, Hancock RE, Neutrophil-derived defensins as modulators of innate immune function, Crit. Rev. Immunol 28 (3) (2008) 185–200. [PubMed: 19024344]
[9]. Yang D, Biragyn A, Kwak LW, Oppenheim JJ, Mammalian defensins in immunity: more than just microbicidal, Trends Immunol. 23 (6) (2002)291–296. [PubMed: 12072367]
[10]. Szyk A, Wu Z, Tucker K, Yang D, Lu W, Lubkowski J, Crystal structures of human alpha-defensins HNP4, HD5, and HD6, Protein Sci. 15 (12) (2006) 2749–2760. [PubMed: 17088326]

[11]. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J, Human beta-defensins, Cell. Mol. Life Sci 63 (11) (2006) 1294–1313. [PubMed: 16710608]

[12]. Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim JJ, Chertov O, Lubkowski J, The structure of human beta-defensin-2 showsevidence of higher order oligomerization, J. Biol. Chem 275 (42) (2000) 32911–32918. [PubMed: 10906336]

[13]. Yamaguchi Y, Nagase T, Makita R, Fukuhara S, Tomita T, Tominaga T, Kurihara H, Ouchi Y, Identification of multiple novel epididymis-specific beta-defensin isoforms in humans and mice, J. Immunol. 169 (5) (2002) 2516–2523. [PubMed: 12193721]

[14]. Schutte BC, Mitros JP, Bartlett JA, Walters JD, Jia HP, Welsh MJ, Casavant TL, McCray PB Jr., Discovery of five conserved beta-defensin gene clusters using a computational search strategy, Proc. Natl. Acad. Sci. U. S. A. 99 (4) (2002) 2129–2133. [PubMed: 11854508]

[15]. Gazdzik T, Selsted ME, Szkwarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI, Defensins. Natural peptide antibiotics of human neutrophils, J. Clin. Invest 76 (4) (1985) 1427–1435. [PubMed: 2997278]

[16]. Wilde CG, Griffith JE, Marra MN, Snable JL, Scott RW, Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family, J. Biol. Chem 264 (19) (1989) 11200–11203. [PubMed: 2500436]

[17]. Shah R, Chang TL, Defensins in viral infection Small Wonder: Peptides for Disease Control, 1095, American Chemical Society, 2012, pp. 137–171.

[18]. Ganz T, Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes, Infect. Immun 55 (3) (1987) 568–571. [PubMed: 3643868]

[19]. Mackewicz CE, Yuan J, Tran P, Diaz L, Mack E, Selsted ME, Levy JA, Alpha-defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors, Aids 17 (14) (2003) F23–F32. [PubMed: 14502030]

[20]. Zaghat GJ, He T, Lopez P, Yu W, Yu J, Zhang L, Alpha-defensins released into stimulated CD8+ T-cell supernatants are likely derived from residual granulocytes within the irradiated allogeneic peripheral blood mononuclear cells used as feeders, J. Acquir. Immune Defic. Syndr 36 (5) (2004) 993–1005. [PubMed: 15247551]

[21]. Selsted ME, Ouellette AJ, Mammalian defensins in the antimicrobial immune response, Nat. Immunol. 6 (6) (2005) 551–557. [PubMed: 15908936]

[22]. Jones DE, Bevins CL, Paneth cells of the human small intestine express an antimicrobial peptide gene, J. Biol. Chem 267 (32) (1992) 23216–23225. [PubMed: 1429669]

[23]. Salzman NH, Underwood MA, Bevins CL, Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa, Semin. Immunol 19 (2) (2007) 70–83. [PubMed: 17485224]

[24]. Spencer JD, Hains DS, Porter E, Bevins CL, DiRosario J, Becknell B, Wang H, Schwaderer AL, Human alpha defensin 5 expression in the human kidney and urinary tract, PLoS One 7 (2) (2012) e31712. [PubMed: 22359618]

[25]. Radeva MY, Jahns F, Wilhelm A, Glei M, Settmacher U, Greulich KO, Mothes H, Defensin alpha 6 (DEFA 6) overexpression threshold of over 60 fold can distinguish between adenoma and fully blown colon carcinoma in individual patients, BMC Cancer 10 (2010) 588. [PubMed: 20979654]

[26]. Nam MJ, Kee MK, Kuick R, Hanash SM, Identification of defensin alpha6 as a potential biomarker in colon adenocarcinoma, J. Biol. Chem 280 (9) (2005) 8260–8265. [PubMed: 15613481]

[27]. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schroder JM, Bevins CL, Fellermann K, Stange EF, NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression, Gut 53 (11) (2004) 1658–1664. [PubMed: 15479689]

[28]. Wehkamp J, Wang G, Kubler I, Nuding S, Gregorieff A, Schnabel A, Kays RJ, Fellermann K, Burk O, Schwab M, Clevers H, Bevins CL, Stange EF, The Paneth cell alpha-defensin deficiency of ileal Crohn’s disease is linked to Wnt/Tcf-4, J. Immunol 179 (5) (2007) 3109–3118. [PubMed: 17709525]
[29]. Porter E, Yang H, Yavagal S, Preza GC, Murillo O, Lima H, Greene S, Mahoozi L, Klein-Patel M, Diamond G, Gulati S, Ganz T, Rice PA, Quayle AJ, Distinct defensin profiles in Neisseria gonorrhoeae and Chlamydia trachomatis urethritis reveal novel epithelial cell-neutrophil interactions, Infect. Immun 73 (8) (2005) 4823–4833. [PubMed: 16040996]

[30]. Fan SR, Liu XP, Liao QP, Human defensins and cytokines in vaginal lavage fluid of women with bacterial vaginosis, Int. J. Gynaecol. Obstet (2008).

[31]. Klotman ME, Rapista A, Teleshova N, Micsenyi A, Jarvis GA, Lu W, Porter E, Chang TL, Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission, J. Immunol 180 (9) (2008) 6176–6185. [PubMed: 18424739]

[32]. Hayashi R, Tsuchiya K, Fukushima K, Horita N, Hibiya S, Kitagaki K, Negi M, Itoh E, Akashi T, Eishi Y, Okada E, Araki A, Ohno H, Nakamura T, Tanaka S, Chayama K, Watanabe M, Reduced human alpha-defensin 6 in noninflamed jejunal tissue of patients with Crohn’s disease, Inflamm. Bowel Dis 22 (5) (2016) 1119–1128. [PubMed: 26891258]

[33]. Yang D, de la Rosa G, Tewary P, Oppenheim JJ, Alarmins link neutrophils and dendritic cells, Trends Immunol. 30 (11) (2009) 531–537. [PubMed: 19699678]

[34]. Sorensen OE, Thapa DR, Rosenthal A, Liu L, Roberts AA, Ganz T, Differential regulation of beta-defensin expression in human skin by microbial stimuli, J. Immunol. 174 (8) (2005) 4870–4879. [PubMed: 15814714]

[35]. Ryan LK, Dai J, Yin Z, Megjugorac N, Uhlhorn V, Yim S, Schwartz KD, Abrahams JM, Diamond G, Fitzgerald-Bocarsly P, Modulation of human [beta]-defensin-1 (hBD-1) in plasmacytoid dendritic cells (PDC), monocytes, and epithelial cells by influenza virus, Herpes simplex virus, and Sendai virus and its possible role in innate immunity, J. Leukoc. Biol 90 (2) (2011) 343–356. [PubMed: 21551252]

[36]. Schaef er TM, Fahey JV, Wright JA, Wira CR, Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly(I:C), J. Immunol 174 (2) (2005) 992–1002. [PubMed: 15634923]

[37]. Duits LA, Nibbering PH, van Strijen E, Vos JB, Manesse-Lazeroms SP, van Sterkenburg MA, Hiemstra PS, Rhinovirus increases human beta-defensin-2 and –3 mRNA expression in cultured bronchial epithelial cells, FEMS Immunol. Med. Microbiol 38 (1) (2003) 59–64. [PubMed: 12900056]

[38]. Uehara A, Takada H, Synergism between TLRs and NOD1/2 in oral epithelial cells, J. Dent. Res 87 (7) (2008) 682–686. [PubMed: 18573991]

[39]. Nagy I, Pivarcsi A, Koreck A, Szell M, Urban E, Kemeny L, Distinct strains of Propionibacterium acnes induce selective human beta-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors, J. Invest. Dermatol 124 (5) (2005) 931–938. [PubMed: 15854033]

[40]. Pivarcsi A, Nagy I, Koreck A, Kis K, Kenderessy-Szabo A, Szell M, Dobozy A, Kemeny L, Microbial compounds induce the expression of pro-inflammatory cytokines, chemokines and human beta-defensin-2 in vaginal epithelial cells, Microbes Infect. 7 (2005) 1117–1127. [PubMed: 1583496]

[41]. Guilloteau K, Paris I, Pedretti N, Boniface K, Juchaux F, Huguer V, Guillet G, Bernard FX, Lecron JC, Morel F, Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1 [alpha], and TNF-[alpha] recapitulates some features of psoriasis, J. Immunol 184 (9) (2010) 5263–5270. [PubMed: 20335534]

[42]. Kao CY, Chen Y, Thai P, Wachi S, Huang F, Kim C, Harper RW, Wu R, IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways, J. Immunol 173 (5) (2004) 3482–3491. [PubMed: 15322213]

[43]. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA, Interleukin (IL)-22 and IL-17 are coexposed by Th17 cells and cooperatively enhance expression of antimicrobial peptides, J. Exp. Med 203 (10) (2006) 2271–2279. [PubMed: 16982811]

[44]. Kawas HI, Weinberg A, Hirsch SA, Venizelos A, Howell S, Jiang B, Jin G, Overexpression of human beta-defensin-3 in oral dysplasia: potential role in macrophage trafficking, Oral Oncol. 45 (8) (2009) 696–702. [PubMed: 19097930]
[45]. Huang F, Kao CY, Wachi S, Thai PH, Ryu J, Wu R, Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells, J. Immunol 179 (10) (2007) 6504–6513. [PubMed: 17982039]

[46]. Jang BC, Lim KJ, Suh MH, Park JG, Suh SI, Dexamethasone suppresses interleukin-Ibeta-induced human beta-defensin 2 mRNA expression: involvement of p38 MAPK, JNK, MKP-1, and NF-kappaB transcriptional factor in A549 cells, FEMS Immunol. Med. Microbiol 51 (1) (2007) 171–184. [PubMed: 17645739]

[47]. Kao CY, Kim C, Huang F, Wu R, Requirements for two proximal NF-kappaB binding sites and IkappaB-zeta in IL-17A-induced human beta-defensin 2 expression by conducting airway epithelium, J. Biol. Chem 283 (22) (2008) 15309–15318. [PubMed: 18362142]

[48]. Pernet I, Reymermier C, Guezennec A, Branka JE, Guesnet J, Perrier E, Dezutter-Dambuyant C, Schmitt D, Viaj J, Calcium triggers beta-defensin (hBD-2 and hBD-3) and chemokine macrophage inflammatory protein-3 alpha (MIP-3alpha/CCL20) expression in monolayers of activated human keratinocytes, Exp. Dermatol 12 (6) (2003) 755–760. [PubMed: 14714554]

[49]. Janeway CA Jr., Travers P, Walport M, Shlomchik MJ, Immunobiology: The Immune System in Health and Disease, 5th ed., Garland Science, New York, 2001.

[50]. Chertov O, Michiel DF, Xu L, Wang JM, Tani K, Murphy WJ, Longo DL, Taub DD, Oppenheim JJ, Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemotactic proteins released from interleukin-8-stimulated neutrophils, J. Biol. Chem 271 (6) (1996)2935–2940. [PubMed: 8621683]

[51]. Territo MC, Ganz T, Selsted ME, Lehrer R, Monocyte-chemotactic activity of defensins from human neutrophils, J. Clin. Invest 84 (6) (1989) 2017–2020. [PubMed: 2592571]

[52]. Yang D, Chen Q, Chertov O, Oppenheim JJ, Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells, J. Leukoc. Biol 68 (1) (2000) 9–14. [PubMed: 10914484]

[53]. Grigat J, Soruri A, Forssmann U, Riggert J, Zwirner J, Chemotraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human alpha-defensin family, J. Immunol 179 (6) (2007) 3958–3965. [PubMed: 17785833]

[54]. Tecle T, White MR, Gantz D, Crouch EC, Hartshorn KL, Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses, J. Immunol 178 (12) (2007) 8046–8052. [PubMed: 17548642]

[55]. Shi J, Aono S, Lu W, Ouellette AJ, Hu X, Ji Y, Wang L, Lenz S, van Ginkel FW, Liles M, Dykstra C, Morrison EE, Elson CO, A novel role for defensins in intestinal homeostasis: regulation of IL-1beta secretion, J. Immunol 179 (2) (2007) 1245–1253. [PubMed: 17617617]

[56]. Van Wetering S, Mannesse-Lazeroms SP, Van Sterkenburg MA, Daha MR, Dijkman JH, Hiemstra PS, Effect of defensins on interleukin-8 synthesis in airway epithelial cells, Am. J. Physiol 272 (5 Pt. 1) (1997) L888–L896. [PubMed: 9176253]

[57]. Guo CJ, Tan N, Song L, Douglas SD, Ho WZ, Alpha-defensins inhibit HIV infection of macrophages through upregulation of CC-chemokines, AIDS 18 (8) (2004) 1217–1218. [PubMed: 1516542]

[58]. de Leeuw E, Burks SR, Li X, Kao JP, Lu W, Structure-dependent functional properties of human defensin 5, FEBS Lett. 581 (3) (2007) 515–520. [PubMed: 17250830]

[59]. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, Zal T, Mellman I, Schroder JM, Liu YJ, Gillett M, Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide, Nature 449 (7162) (2007) 564–569. [PubMed: 17873860]

[60]. Chamilos G, Gregorio J, Meller S, Lande R, Kontoyiannis DP, Modlin RL, Gillett M, Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37, Blood 120 (18) (2012) 3699–3707. [PubMed: 22927244]

[61]. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gillett M, Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8, J. Exp. Med 206 (9) (2009) 1983–1994. [PubMed: 19703986]
[62]. Papayannopoulos V, Neutrophil extracellular traps in immunity and disease, Nat. Rev. Immunol 18 (2) (2017) 134–147. [PubMed: 28990587]

[63]. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S, Chamilos G, Sebasigari R, Ricciere V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M, Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus, Sci. Transl. Med 3 (73) (2011) 73ra19.

[64]. Nassar T, Akkawi S, Bar-Shavit R, Haj-Yehia A, Bdeir K, Al-Mehdi AB, Tarshis M, Higazi AA, Human alpha-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor, Blood 100 (12) (2002) 4026–4032. [PubMed: 12393692]

[65]. Higazi AA, Nassar T, Ganz T, Rader DJ, Udassin R, Bdeir K, Hiss E, Sachais BS, Williams KJ, Leitersdorf E, Cines DB, The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells; a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis, Blood 96 (4) (2000) 1393–1398. [PubMed: 10942383]

[66]. Higazi AA, Ganz T, Kariko K, Cines DB, Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells, J. Biol. Chem 271 (30) (1996) 17650–17655. [PubMed: 8663495]

[67]. Charp PA, Rice WG, Raynor RL, Reimund E, Kinkade JM Jr., Ganz T, Selsted ME, Lehrer RI, Kuo JF, Inhibition of protein kinase C by defensins, antibiotic peptides from human neutrophils, Biochem. Pharmacol 37 (5) (1988) 951–956. [PubMed: 3345204]

[68]. Chang TL, Vargas J Jr., DelPortillo A, Klotman ME, Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity, J. Clin. Invest 115 (3) (2005) 765–773. [PubMed: 15719067]

[69]. Salvatore M, Garcia-Sastre A, Ruchala P, Lehrer RI, Chang T, Klotman ME, Alpha-defensin inhibits influenza virus replication by cell-mediated mechanism(s), J. Infect. Dis 196 (6) (2007) 835–843. [PubMed: 17704137]

[70]. van den Berg RH, Faber-Krol MC, van Wetering S, Hiemstra PS, Daha MR, Inhibition of activation of the classical pathway of complement by human neutrophil defensins, Blood 92 (10) (1998) 3898–3903. [PubMed: 9808583]

[71]. Groeneveld TW, Ramwadhdoebe TH, Trouw LA, van den Ham DL, van der Borden V, Drijfhout JW, Hiemstra PS, Daha MR, Roos A, Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation, Mol. Immunol 44 (14) (2007) 3608–3614. [PubMed: 17448537]

[72]. Masera RG, Bateman A, Muscettola M, Solomon S, Angeli A, Corticostatins/defensins inhibit in vitro NK activity and cytokine production by human peripheral blood mononuclear cells, Regul. Pept 62 (1) (1996) 13–21. [PubMed: 8738877]

[73]. Grutkoski PS, Graeber CT, Lim YP, Ayala A, Simms HH, Alpha-defensin 1 (human neutrophil protein 1) as an antichemotactic agent for human polymorphonuclear leukocytes, Antimicrob. Agents Chemother 47 (8) (2003) 2666–2668. [PubMed: 12878538]

[74]. Miles K, Clarke DJ, Lu W, Sibinska Z, Beaumont PE, Davidson DJ, Barr TA, Campopiano DJ, Gray M, Dying and necrotic neutrophils are anti-inflammatory secondary to the release of alpha-defensins, J. Immunol 183 (3) (2009) 2122–2132. [PubMed: 19596979]

[75]. Brook M, Tomlinson GH, Miles K, Smith RW, Rossi AG, Hiemstra PS, van’t Wout EF, Dean JL, Gray NK, Lu W, Gray M, Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation, Proc. Natl. Acad. Sci. U. S. A 113 (16) (2016) 4350–4355. [PubMed: 27044108]

[76]. Biswas A, Liu YJ, Hao L, Mizoguchi A, Salzman NH, Bevins CL, Kobayashi KS, Induction and rescue of nod2-dependent th1-driven granulomatous inflammation of the ileum, Proc. Natl. Acad. Sci. U. S. A 107 (33) (2010) 14739–14744. [PubMed: 20679225]

[77]. Khine AA, Del Sorbo L, Vaschetto R, Voglis S, Tullis E, Slutsky AS, Downey GP, Zhang H, Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway, Blood 107 (7) (2006) 2936–2942. [PubMed: 16322472]

[78]. Nagaoka I, Suzuki K, Murakami T, Niyonsaba F, Tamura H, Hirata M, Evaluation of the effect of alpha-defensin human neutrophil peptides on neutrophil apoptosis, Int. J. Mol. Med 26 (6) (2010) 925–934. [PubMed: 21042789]
[79]. Ibusuki K, Sakiyama T, Kanmura S, Maeda T, Ishiwata Y, Nasu Y, Sasaki F, Taguchi H, Hashimoto S, Numata M, Uto H, Tsubouchi H, Idoo A, Human neutrophil peptides induce interleukin-8 in intestinal epithelial cells through the P2 receptor and ERK1/2 signaling pathways, Int. J. Mol. Med 35 (6) (2015) 1603–1609. [PubMed: 25816245]

[80]. Syeda F, Liu HY, Tullis E, Liu M, Slutsky AS, Zhang H, Differential signaling mechanisms of HNP-induced IL-8 production in human lung epithelial cells and monocytes, J. Cell. Physiol 214 (3) (2008) 820–827. [PubMed: 17786963]

[81]. Wang F, Qiao L, Lv X, Trivet A, Yang R, Oppenheim JJ, Yang N Zhang, Alarmin human alpha defensin HNP1 activates plasmacytid dendritic cells by triggering NF-kappaB and IRF1 signaling pathways, Cytokine 83 (2016) 53–60. [PubMed: 27031443]

[82]. Chen Q, Jin Y, Zhang K, Li H, Chen W, Meng G, Fang X, Alarmin HNP-1 promotes pyroptosis and IL-1beta release through different roles of NLRP3 inflammasome via P2X7 in LPS-primed macrophages, Innate Immun. 20 (3) (2014) 290–300. [PubMed: 23792296]

[83]. Presicce P, Giannelli S, Taddeo A, Villa ML, Della Bella S, Human defensins activate monocyte-derived dendritic cells, promote the production of proinflammatory cytokines, and up-regulate the surface expression of CD91, J. Leukoc. Biol 86 (4) (2009) 941–948. [PubMed: 19477909]

[84]. Soruri A, Grigat J, Forssmann U, et al., Beta-defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved, Eur. J. Immunol 37 (2007) 2474–2486. [PubMed: 17705135]

[85]. Yang D, Chertov O, Bykovskiaia SN, Chen Q, Bufo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ, Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6, Science 286 (5439) (1999) 525–528. [PubMed: 10521347]

[86]. Bonitto M, Jordan WJ, Eskdale J, Tossi A, Antcheva N, Crovella S, Connell ND, Gallagher G, Human beta-defensin 2 induces a vigorous cytokine response in peripheral blood mononuclear cells, Antimicrob. Agents Chemother 50 (4) (2006) 1433–1441. [PubMed: 16569862]

[87]. Niyonsaba F, Hirata M, Ogawa H, Nagaoka I, Epithelial cell-derived antibacterial peptides human beta-defensins and cathelicidin: multifunctional activities on mast cells, Curr. Drug Targets Inflamm. Allergy 2 (3) (2003) 224–231. [PubMed: 14561157]

[88]. Kanda N, Watanabe S, Increased serum human beta-defensin-2 levels in atopic dermatitis: relationship to IL-22 and oncostatin M, Immunobiology 217 (4) (2012) 436–445. [PubMed: 22137028]

[89]. Niyonsaba F, Ogawa H, Nagaoka I, Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils, Immunology 111 (3) (2004) 273–281. [PubMed: 15009427]

[90]. Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I, Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway, Int. Immunol 14 (4) (2002) 421–426. [PubMed: 11934878]

[91]. Wang W, Qu X, Dang X, et al., Human beta-defensin-3 induces IL-8 release and apoptosis in airway smooth muscle cells, Clin. Exp. Allergy 47 (9) (2017) 1138–1149. [PubMed: 28437599]

[92]. Nagaoka I, Niyonsaba F, Tsutsumi-Ishii Y, et al., Evaluation of the effect of human beta-defensins on neutrophil apoptosis, Int. Immunol 20 (2008) 543–553. [PubMed: 18308714]

[93]. Ostaff MJ, Stange EF, Wehkamp J, Antimicrobial peptides and gut microbiota in homeostasis and pathology, EMBO Mol. Med 5 (10) (2013) 1465–1483. [PubMed: 24039130]

[94]. Otte JM, Werner I, Brand S, et al., Human beta defensin 2 promotes intestinal wound healing in vitro, J. Cell. Biochem 104 (2008) 2286–2297. [PubMed: 18449938]

[95]. Ghannam S, Dejou C, Pedretti N, et al., CCL20 and beta-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions, J. Immunol 186 (2011) 1411–1420. [PubMed: 21178014]

[96]. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P, Medvik K, Sieg SF, Weinberg A, Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication, AIDS 17 (16) (2003) F39–F48. [PubMed: 14571200]

[97]. Feng Z, Dubyak GR, Lederman MM, Weinberg A, Cutting edge: human beta defensin 3—a novel antagonist of the HIV-1 coreceptor CXCR4, J. Immunol 177 (2) (2006) 782–786. [PubMed: 16818731]
[98]. Rohrl J, Yang D, Oppenheim JJ, Hehlgans T. Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2, J. Immunol 184 (12) (2010) 6688–6694. [PubMed: 20483750]

[99]. Jin G, Kawsar HI, Hirsch SA, Zeng C, Jia X, Feng Z, Ghosh SK, Zheng QY, Zhou A, McIntyre TM, Weinberg A. An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis, PLoS One 5 (6) (2010) e10993. [PubMed: 20544025]

[100]. Wu Z, Hoover DM, Yang D, Boulegue C, Santamaria F, Oppenheim JJ, Lubkowski J, Lu W. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3, Proc. Natl. Acad. Sci. U. S. A 100 (15) (2003) 8880–8885. [PubMed: 12840147]

[101]. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakho A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2, Science 298 (5595) (2002) 1025–1029. [PubMed: 12417106]

[102]. Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, Weinberg A, Sieg SF. Human -defensin-3 activates professional antigen-presenting cells via toll-like receptors 1 and 2, Proc. Natl. Acad. Sci. U. S. A 104 (47) (2007) 18631–18635. [PubMed: 18006661]

[103]. Funderburg NT, Jadlowsky JK, Lederman MM, et al., The Toll-like receptor ¼ agonists Pam(3) CSK(4) and human beta-defensin-3 differentially induce interleukin-10 and nuclear factor-kB signaling patterns in human monocytes, Immunology 134 (2011) 151–160. [PubMed: 21896010]

[104]. Judge CJ, Reeyes-Aviles E, Conry SJ, Sieg SS, Feng Z, Weinberg A, Anthony DD. HBD-3 induces NK cell activation, IFN-gamma secretion and Mdc dependent cytolytic function, Cell. Immunol. 297 (2) (2015) 61–68. [PubMed: 26302933]

[105]. Lioi AB, Rodriguez AL, Funderburg NT, et al., Membrane damage and repair in primary monocytes exposed to human beta-defensin-3. J. Leukoc. Biol 92 (2012) 1083–1091. [PubMed: 22837529]

[106]. Lioi AB, Ferrari BM, Dubyak GR, et al., Human beta-defensin-3 increases CD86 expression on monocytes by activating the ATP-gated channel P2X7, J. Immunol 195 (2015) 4438–4445. [PubMed: 26416278]

[107]. Meisch JP, Vogel RM, Schlatter DM, et al., Human beta-defensin 3 induces STAT1 phosphorylation, tyrosine phosphatase activity, and cytokines synthesis in T cells, J. Leukoc. Biol 94 (2013) 459–471. [PubMed: 23804808]

[108]. Albanesi C, Fairchild HR, Madonna S, Scarponi C, De Pita O, Leung DY, Howell MD, IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppress orf cytokine signaling (SOCS)-1, and SOCS-3, J. Immunol 179 (2) (2007) 984–992. [PubMed: 17617590]

[109]. Semple F, Webb S, Li HN, et al., Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo, Eur. J. Immunol 40 (2010) 1073–1078. [PubMed: 20104911]

[110]. Semple F, MacPherson H, Webb S, Cox SL, Mallin LJ, Tyrrell C, Grimes GR, Semple CA, Nix MA, Millhauser GL, Dorin JR, Human beta-defensin 3 affects the activity of pro-inflammatory pathways associated with MyD88 and TRIF, Eur. J. Immunol 41 (11) (2011) 3291–3300. [PubMed: 21809339]

[111]. Tewary P, de la Rosa G, Sharma N, et al., Beta defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-alpha production by human plasmacytoid dendritic cells and promote inflammation, J. Immunol 191 (2013) 865–874. [PubMed: 23776172]
[115]. Lande R, Chamilos G, Ganguly D, et al., Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA, Eur. J. Immunol 45 (2015) 203–213. [PubMed: 25332209]

[116]. McGlasson SL, Semple F, MacPherson H, et al., Human beta-defensin 3 increases the TLR9-dependent response to bacterial DNA, Eur. J. Immunol 47 (2017) 658–664. [PubMed: 28102569]

[117]. De Paula VS, Gomes NS, Lima LG, Miyamoto CA, Monteiro RQ, Almeida FC, Valente AP, Structural basis for the interaction of human beta-defensin 6 and its putative chemokine receptor CCR2 and breast cancer microvesicles, J. Mol. Biol 425 (22) (2013) 4479–4495. [PubMed: 23938203]

[118]. De Paula VS, Pomin VH, Valente AP, Unique properties of human beta-defensin 6 (hBD6) and glycosaminoglycan complex: sandwich-like dimerization and competition with the chemokine receptor 2 (CCR2) binding site, J. Biol. Chem 289 (33) (2014) 22969–22979. [PubMed: 24970887]

[119]. Wang J, Xi L, Hunt JL, Gooding W, Whiteside TL, Chen Z, Godfrey TE, Ferris RL, Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype, Cancer Res. 64 (5) (2004) 1861–1866. [PubMed: 14996750]

[120]. Mburu YK, Abe K, Ferris LK, Sarkar SN, Ferris RL, Human beta-defensin 3 promotes NF-kappaB-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck, Carcinogenesis 32 (2) (2011) 168–174. [PubMed: 21071608]

[121]. Weinberg A, Jin G, Sieg S, McCormick TS, The yin and yang of human Beta-defensins in health and disease, Front. Immunol 3 (2012) 294. [PubMed: 23060878]

[122]. Lu Q, Samaranayake LP, Darveau RP, Jin L, Expression of human beta-defensin-3 in gingival epithelia, J. Periodontal Res 40 (6) (2005) 474–481. [PubMed: 16302926]
Fig. 1.
A. Human α-defensins, B. Human β-defensins.
Table 1.

Receptors and pathways involved in immune functions of human defensins.

| Defensins       | Receptors/Signaling                                      | Function                                      | Cell Type                                      | References |
|-----------------|--------------------------------------------------------|-----------------------------------------------|------------------------------------------------|------------|
| HNP1            | P2Y receptor                                           | Block apoptosis                               | neutrophils                                   | [78]       |
| P2 receptor (but not P2Y6), ERK1/2, p38 | Induce IL-8                                           | intestinal epithelial cell lines              | [79]       |
| NF-κB, IRF1     | Induce IFNα, IFNβ, IL-6, enhance TLR9 activation       | pDCs                                          | [81]       |
| P2X7-potassium channel efflux-caspase-1 signaling pathway | Activate NLRP3 inflammasome, induce IL-1β         | LPS-primed THP-1 monocytic cell line          | [82]       |
| HNP1, HNP3, HD5 | Gαi protein-coupled receptor, MAPK ERK1/2, p38         | Chemotaxis                                    | macrophages, mast cells                        | [53]       |
| hBD1            | CCR6                                                   | Chemotaxis                                    | HEK293 CCR6 expressing cells                  | [85]       |
| hBD2            | CCR6                                                   | Chemotaxis                                    | memory CD4+ T cells, immature DCs             | [85]       |
|                 | CCR6                                                   | Cell migration (wound healing), block TRAIL-mediated apoptosis | intestinal epithelial cell lines              | [94]       |
|                 | CCR6                                                   | Adhere to inflamed endothelial cells          | Th17 cells                                    | [95]       |
|                 | ERK1/2, JNK, p38 MAPK                                  | Chemotaxis                                    | MDMs                                          | [84]       |
|                 | CCR6, Gαi protein-coupled PLC                          | Chemotaxis                                    | TNFα-stimulated neutrophils                   | [89]       |
|                 | Gαi protein-coupled PLC                                | Chemotaxis                                    | mast cells                                    | [90]       |
| hBD3            | CCR6, ERK1/2 MAPK                                      | Induce IL-8, apoptosis                        | airway smooth muscle cells                    | [91]       |
|                 | CCR6                                                   | Block apoptosis                               | Neutrophils                                   | [92]       |
|                 | CCR2                                                   | Induce IL-1α, IL-6, IL-8, CCL18, TNFα        | MDMs                                          | [99]       |
|                 | CCR2                                                   | Recruitment                                   | monocytes, macrophages (tumor-associated)     | [99]       |
|                 | CXCR4                                                  | Chemotaxis                                    | activated CD4+ T cells, CD4+ T cell line      | [96, 97]   |
|                 | MyD88, IRAK-1 activation                               | Activation                                    | monocytes                                     | [102]      |
|                 | TLR1/2                                                 | Activation                                    | monocytes, mDCs                               | [102]      |
|                 | TLR1/2                                                 | Induce IL-1β                                  | monocytes                                     | [103]      |
|                 | TLR1/2, CCR2                                           | Induce CD69                                   | NK cells                                      | [104]      |
| Defensins | Receptors/Signaling | Function       | Cell Type               | References |
|-----------|--------------------|----------------|-------------------------|------------|
| TLR9      |                    | Activation     | pDCs, mDCs              | [114]      |
| TLR9      |                    | Induce IFNα, IL-6 | murine DCs, PBMCs     | [116]      |
| P2X7 receptor |               | Induce CD86     | monocytes               | [106]      |
| STAT1     |                    | N/A            | activated CD4+ T cells | [108]      |
| hBD2/hBD3 | MrgX2              | Degranulation  | mast cells              | [107]      |
| hBD2-IgFc, hBD3-IgFc, mBD4-IgFc, mBD14-IgFc | | Chemotaxis | HEK293-CCR2 expressing cells | [98] |
| hBD3-IgFc, mBD14-IgFc | | Chemotaxis | monocytes | [98] |
| mBD2-IgFc | CCR6               | Chemotaxis     | bone marrow derived DCs | [101]      |
| TLR4      |                    | Maturation     | Immature DCs           | [101]      |